Viking Therapeutics, Inc. (VKTX) Institutional Ownership & Insider Trading

433 institutions reported holding Viking Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 21 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VKTXViking Therapeutics, Inc.Follow VKTX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 2.8B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 28 Oct, in 4 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

433 institutions held 65.0% of the shares. Across filers that reported both quarters, shares held changed +3.2%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	433	76	+3.2%	129	60	111	39
Mar 26	406	73	+5.1%	144	46	98	58
Dec 25	416	72	-3.1%	104	73	122	33
Sep 25	361	74	-1.6%	130	39	98	57
Jun 25	390	76	-2.7%	132	70	97	48
Mar 25	366	76	-5.5%	150	52	92	90
Dec 24	400	82	-3.8%	133	58	113	79
Sep 24	415	82	+1.6%	159	84	95	52

Viking Therapeutics, Inc. — questions

Who owns Viking Therapeutics, Inc. stock?: 433 institutions reported Viking Therapeutics, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: FMR LLC (5.4%), BlackRock, Inc. (5.3%), STATE STREET CORP (4.8%).
Are Viking Therapeutics, Inc. insiders buying or selling?: 21 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Viking Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.